Myopowers Medical Technologies

About:

Myopowers Medical Technologies is focused on the development of artificial muscles for the treatment of severe incontinences.

Website: http://www.myopowers.com

Top Investors: Novartis Venture Fund, Truffle Capital, BlueOcean Ventures, Gran Plasa

Description:

Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area. The company focus is the development of ARTUS, a new and unique implantable device for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation. ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market.

Total Funding Amount:

$21.1M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Besançon, Franche-Comte, France

Founded Date:

2004-01-01

Contact Email:

info(AT)myopowers.com

Founders:

Daniel Hayoz, Piergiorgio Tozzi

Number of Employees:

11-50

Last Funding Date:

2015-06-16

IPO Status:

Private

Industries:

© 2025 bioDAO.ai